Samulski’s scientific leadership has led to the development of novel self-complementary AAV vectors, Chimeric AAV capsids, the first use of AAV for gene delivery to the Central Nervous System (CNS), ...

By comparing structural features across AAV serotypes with shared or disparate patterns of tropism, scientists can design chimeric AAVs by combining features from multiple natural serotypes to ...

Chimeric antigen receptor (CAR ... Based on their inherent safety, AAV vectors, which are most commonly used to deliver therapeutic genes directly to patients and are currently the technology ...

Early chimera research was difficult and inexact ... today announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adeno-associated virus (AAV) serotypes 2 and 8, enabling determination of ...

AAV with uniquely characterised autoantigens provides an opportunity for MPO-specific or PR3-specific B cell depletion. The development of chimeric autoantibody receptor T cells would then enable long ...

We dosed our first patients in our clinical trials evaluating our gamma delta 1 chimeric antigen receptor ... trial beyond LN to include SLE, SSc and AAV. In November 2024, Adicet announced ...